A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf.
2022-RA-1078-ESGO Service evaluation of women with stage 1b vulval cancer who underwent groin sentinel lymph node biopsy: The South East Wales Gynaecological Oncology Centre (SEWGOC) experience
2022
Vaginal and vulvar cancer
unpublished
Preserved Fulltext
2022-RA-1044-ESGO Table 2 Conclusion Since the closure of the GROINNS-2 trial we have continued with sentinel lymph node identification for women with clinical early stage vulval cancer. We have shown high level of adherence to the GROINNS trial protocol. There were a few patients managed as day-case which was of benefit to the patients.
doi:10.1136/ijgc-2022-esgo.946
fatcat:fd4daiw445fd5hkkz2ehl2f34i